Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mary Beth Rodal"'
Autor:
Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens, Hope S. Rugo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Meth
Externí odkaz:
https://doaj.org/article/26e5bc3db4084f12bdaf56d54e8bff23
Autor:
Brian L. West, Mai H. Le, Robert Wesolowski, David A. Karlin, Laura Reebel, Mary Beth Rodal, Paul Severson, Afshin Dowlati, Alexandra Peck, Lisa M. Coussens, Hope S. Rugo, Neelesh Sharma, Adhirai Marimuthu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Meth
Autor:
Joseph A. Bokar, Balazs Halmos, Rosalyn A. Juergens, David J. Adelstein, Pingfu Fu, Mary Beth Rodal, Yuxia Jia, Afshin Dowlati
Publikováno v:
Investigational New Drugs. 31:1244-1250
Introduction This study aimed to assess the safety and tolerability of the multitargeted tyrosine kinase inhibitor, vandetanib (V), in combination with two chemotherapeutic agents, oxaliplatin (O) and docetaxel (D) in advanced gastroesophageal (GE) c
Autor:
Mary Beth Rodal, A. Ness, Afshin Dowlati, Robert Dreicer, Smitha S. Krishnamurthi, Joseph A. Bokar, Joseph Gibbons, Charles J. Nock, Scot C. Remick, Matthew M. Cooney
Publikováno v:
Cancer chemotherapy and pharmacology. 70(5)
To determine the safety, the maximal tolerated dose, and to assess for any clinical activity of pomalidomide given to patients with advanced solid tumors.Patients with incurable solid tumors were enrolled. Two different dosing schedules were explored
Autor:
Panayiotis Savvides, Mary Beth Rodal, Jan H. Beumer, Smitha S. Krishnamurthi, Joseph Gibbons, Neelesh Sharma, John J. Pink, Neal J. Meropol, Jennifer R. Eads, Joseph A. Bokar, Pingfu Fu, Stanton L. Gerson, John Riendeau, Yan Xu, Joel N. Saltzman, Henry B. Koon, Donna Kane, Afshin Dowlati, Kristi Beatty, Julianne Czalkiewicz
Publikováno v:
Journal of Clinical Oncology. 33:2558-2558
2558 Background: Temozolomide (TMZ) is an alkylating agent that generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) is a small molecule that potentiates TMZ by binding to apurinic and
Autor:
Neelesh Sharma, Hope S. Rugo, Mary Beth Rodal, David A. Karlin, Lisa M. Coussens, Robert Wesolowski, Laura Reebel, Mai H. Le, Adhirai Marimuthu, Alexandra Peck, Afshin Dowlati, Brian L. West
Publikováno v:
Annals of Oncology. 25:iv148
Aim: CSF1R kinase regulates the recruitment of macrophages to tumors and osteoclast differentiation leading to bone lysis. PLX3397 (PLX), a small molecule CSF1R inhibitor, blocked paclitaxel (TAX) -induced macrophage infiltration in mouse tumor model
Autor:
Neal J. Meropol, Carol Zhao, Bridget Waluch, Afshin Dowlati, Joseph A. Bokar, Mary Beth Rodal, Alison L. Hannah, Ramesh K. Ramanathan, Manpreet K. Chadha, Glen J. Weiss, Catherine Patricia Mast, Ute Hoch, Smitha S. Krishnamurthi, Gayle S. Jameson
Publikováno v:
Journal of Clinical Oncology. 32:550-550
550 Background: Etirinotecan pegol (EP; NKTR-102) is the first long-acting topoisomerase I inhibitor designed to concentrate and provide continuous tumor exposure. This study was designed to identify the recommended dose of EP in combination with 5-f
Autor:
Mary Beth Rodal, Afshin Dowlati, Balazs Halmos, Pingfu Fu, Joseph A. Bokar, Rosalyn A. Juergens, David J. Adelstein
Publikováno v:
Journal of Clinical Oncology. 29:e14644-e14644
e14644 Background: Metastatic gastroesophageal carcinoma is a devastating illness and there is a strong need for improved therapies incorporating novel targeted agents, such as anti-angiogenic agen...
Autor:
P. Savvides, Charles J. Nock, Smitha S. Krishnamurthi, L. Henderson, Mary Beth Rodal, Robert Dreicer, Afshin Dowlati, Joseph A. Bokar, Matthew M. Cooney
Publikováno v:
Journal of Clinical Oncology. 28:e13077-e13077
e13077 Background: Pomalidomide is an IMiD analogue of thalidomide and on an equimolar basis in vitro, displays a greater stimulation of apoptosis, inhibition of COX-2 production, and inhibition of...